VA
CYTK icon

Vident Advisory’s Cytokinetics CYTK Stock Holding History

Vident Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
17,069
+614
+4% +$39K 0.01% 828
2025
Q4 		$1.05M Buy
16,455
+234
+1% +$14.6K 0.01% 786
2025
Q3 		$892K Buy
+16,221
New +$668K 0.01% 881
2024
Q4 		– Sell
-4,195
Closed -$221K – 1473
2024
Q3 		$221K Buy
+4,195
New +$234K 0.01% 1270

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vident Advisory's CYTK Position: Q1 2026 in Review

Vident Advisory increased its Cytokinetics (CYTK) stake by 3.7% in Q1 2026, buying an estimated $39K and bringing the position to 17,069 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #828.

Vident Advisory first reported a position in CYTK in Q3 2024 and has held it in 4 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Vident Advisory held 17,069 shares of Cytokinetics worth $1.13M as of Q1 2026.
  • Vident Advisory bought 614 Cytokinetics shares in Q1 2026, an estimated $39K.
  • Cytokinetics made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #828 holding.
  • Vident Advisory first reported a position in Cytokinetics in Q3 2024 and has held it in 4 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.